Delivering Novel Therapies for RAS/MAPK Pathway Driven Cancers

Doctor with hand on patient's shoulder

Our combination therapy is FDA-approved for KRAS-mutant recurrent low-grade serous ovarian cancer.

Breaking through barriers in aggressive cancers

With nearly a third of all cancers associated with alterations in the RAS/MAPK pathway, these highly aggressive cancers often recur, with patients rarely experiencing optimal outcomes. We are bold in our commitment to inhibit this pathway, discover novel options, and ultimately redefine hope to address this urgent need.  
Two coworkers talking while looking at a laptop

Innovation on a mission

Our clinical program is powered by a robust portfolio of ongoing trials and strategic collaborations, centered on novel small molecule inhibitors targeting the critical RAS/MAPK signaling pathway in cancer. This is the driving force fueling innovative edge of our pipeline through the purposeful use of  combination therapies.Â